| 8:00 | | Registration Opens | |
| 08:30 | 08:40 | Introduction | |
| | Session 1 | ATMP production and translation |
| 08:40 | 09:15 | Zsolt Sebestyen, UMC Utrecht | Biomimetic strategies to guide rational immune receptor-based drug development |
| 09:15 | 09:35 | Luka Fajs, Bio-ReCell | Closed-System Non-Magnetic Cell Separation and Activation Approaches for T Cell Manufacturing |
| 09:35 | 09:55 | Lenka Sučková, Masaryk University | From Clinical Trial to Patient Access: Practical Lessons from the First Czech Hospital Exemption for an Academic ATMP |
| 09:55 | 10:15 | Matija Povh, Sartorious BIA Separations | Improved Development of LNP Formulation for Organ Targeting using Chromatographic Tools |
| 10:15 | 10:45 | Break and Poster Session downstairs | Sponsored Presentation Omega ThermoFisher |
| | Session 2 | From in vivo models to treatments |
| 10:45 | 11:20 | Jan Prochazka, CCP-IMG | Integrated Phenotyping: From Disease Mechanisms to Therapeutic Endpoints |
| 11:20 | 11:40 | Tomaz Martini , Inst. of Biomed. Sciences, UM | Novel-Modality Therapeutic Opportunities in Hyperlipidemia Based on the Discovery of the Sexually Dimorphic Hepatic Cycle of Very-Low-Density Lipoproteins |
| 11:40 | 12:00 | Giulia Bortolussi , ICGEB Trieste | HepCycle-Track Quantifies Hepatocyte Proliferation to Define Therapeutic Timing as a Precision Parameter for Gene Therapy and Genome Editing |
| 12:00 | 12:20 | Špela Malenšek, Kemijski Inštitut | Immunoengineering genetically encoded chimeric PCSK9 vaccine against hypercholesterolemia. |
| 12:20 | 14:00 | Lunch Break and Poster Session downstairs | Sponsored Presentation Sartorius |
| | Session 3 | Advances in gene, cell and tissue therapies |
| 14:00 | 14:35 | Massimo Dominici, Univ. Modena & Reggio Emilia | Engineering Cells to Defeat Refractory Solid Tumors: From MSC-Based Therapeutics to CAR-Driven Immunotherapy |
| 14:35 | 14:55 | Aleksandar Janev, Institute of Cell Biology, UL | Human Amniotic Membrane Preparations Exert a Tumour-Selective Anti-Cancer Effect in Bladder Cancer Across 2D, 3D, and Patient-Derived Models |
| 14:55 | 15:15 | Petra Susjan Leite, Kemijski Inštitut | Making One Copy Count — RNA-Based Therapeutic Strategies in CTNNB1 Haploinsufficiency |
| 15:15 | 15:35 | Duško Lainšček , Kemijski Inštitut | Decoupling reactogenicity from efficacy enables safer mRNA vaccines, AAV gene delivery, and in vivo base editing |
| 15:35 | 16:05 | Coffee Break and Poster Session downstairs | Sponsored Presentation Miltenyi Biotec, Labormed |
| | Session 4 | Cellular models for mechanistic and safety studies |
| 16:05 | 16:40 | Sebastian Diecke, Max Delbrück Center | Pluripotent Stem Cells, Automation, Disease Modeling and beyond |
| 16:40 | 17:00 | Nina Krako Jakovljevic , UCCS | Altered Mitochondrial Respiratory Function and Morphology of Palmitate Induced Hepatocellular Carcinoma Cells: Model of Hepatic Insulin Resistance and Lipotoxcity |
| 17:00 | 17:20 | Bernarda Majc , National Institute of Biology | Overcoming glioblastoma resistance: enhancing standard and nk cell therapies through tgf-β pathway inhibition |
| 17:20 | 17:40 | David Morrow, EATRIS | From Innovation to Access: How Effective European Collaboration Can Transform the ATMP Landscape |
| 17:40 | | End of the conference | |
